三联抗栓治疗出院适宜性与安全性分析
单中心回顾性病历审查纳入93例出院时接受三联抗栓治疗的患者,依据2020年ACC共识评估适宜性。仅31例(33%)治疗适宜,三联治疗疗程过长是最常见不适宜原因;30天内大出血发生率4.3%,因出血再入院率14天为2.2%、30天为6.5%,2例死亡。
要点
- 仅约三分之一出院三联抗栓患者完全符合2020年ACC共识。
- 疗程过长是三联抗栓治疗不适宜的最常见原因。
- 三联抗栓30天内大出血发生率4.3%,需关注出血风险。
核心结论
- 在本单中心研究中,出院时接受三联抗栓治疗的患者中仅三分之一适宜遵循2020年ACC共识声明。
研究设计与样本
- 主要终点为出院时三联抗栓治疗适宜率,适宜性为基于2020年ACC共识声明的复合终点,需满足正确指征、药物、剂量和30天疗程。
主要发现
- 93例患者中31例(33%)接受了适宜的三联抗栓治疗。
- 三联抗栓治疗疗程过长是治疗未达到主要终点的最常见原因。
- 因出血再入院率14天为2.2%,30天为6.5%。
- 三联治疗启动30天内,4.3%的患者发生国际血栓与止血学会定义的大出血,2例患者死亡。
关键数值与推荐
- 适宜三联抗栓治疗需同时满足正确指征、药物、剂量和30天疗程(基于2020年ACC共识声明)。
临床怎么用
- 临床药师应依据2020年ACC共识审核三联抗栓治疗的指征、药物选择、剂量和疗程,重点关注避免疗程过长。
- 出院时应评估出血风险并监测大出血事件,必要时考虑胃肠道预防。
局限性
- 本研究为单中心回顾性病历审查,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze the appropriateness of triple-antithrombotic therapy based on the 2020 American College of Cardiology (ACC) consensus statement while evaluating safety outcomes for patients with respect to adverse events. METHODS: A single-center, retrospective chart review was conducted using electronic medical records from December 18, 2020, to August 31, 2022. The primary endpoint was the rate of appropriateness for triple-antithrombotic therapy in patients discharged from Ochsner LSU Health Shreveport. Appropriateness was a composite endpoint extrapolated from the 2020 ACC consensus statement. For therapy to be defined as appropriate, patients had to have had the correct therapy indication, medications, dosing, and 30-day duration. Secondary safety endpoints included the percentage of patients rehospitalized at 14 and 30 days, the rate of major bleeding events, and the percentage of patients on gastrointestinal prophylaxis while on triple-antithrombotic therapy. RESULTS: A total of 93 patients were included in the study, of whom 31 (33%) received appropriate triple-antithrombotic therapy. Prolonged duration of triple-antithrombotic therapy was the most common reason that therapy did not meet the primary endpoint. The readmission rate due to bleeding was 2.2% at 14 days and 6.5% at 30 days. Within 30 days of initiation of triple therapy, 4.3% of patients endured major bleeding as defined by the International Society on Thrombosis and Hemostasis and 2 patients died. CONCLUSION: In this single-center study, triple-antithrombotic therapy appropriately adhered to the 2020 ACC consensus statement for one-third of patients discharged on this therapy.
引用
- Robichaux T, Edwards K, Carter A, et al. Analysis of appropriateness and safety when discharging patients on triple-antithrombotic therapies. Am J Health Syst Pharm. 2024. PMID: 38487864. doi:10.1093/ajhp/zxae068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。